Pulmonx Co. (NASDAQ:LUNG) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP decreased its position in shares of Pulmonx Co. (NASDAQ:LUNG) by 5.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,000 shares of the company’s stock after selling 4,900 shares during the period. Two Sigma Advisers LP owned about 0.23% of Pulmonx worth $611,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. BNP Paribas Financial Markets acquired a new position in Pulmonx during the 4th quarter worth about $43,000. ProShare Advisors LLC acquired a new position in Pulmonx during the 4th quarter worth about $72,000. Stifel Financial Corp acquired a new position in Pulmonx during the 4th quarter worth about $81,000. SG Americas Securities LLC lifted its stake in Pulmonx by 27.0% during the 4th quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock worth $106,000 after acquiring an additional 3,310 shares in the last quarter. Finally, Graham Capital Management L.P. lifted its stake in Pulmonx by 73.3% during the 4th quarter. Graham Capital Management L.P. now owns 18,071 shares of the company’s stock worth $123,000 after acquiring an additional 7,641 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Analysts Set New Price Targets

LUNG has been the topic of several research reports. D. Boral Capital reissued a “buy” rating and set a $17.00 target price on shares of Pulmonx in a research note on Thursday, May 1st. Jefferies Financial Group initiated coverage on Pulmonx in a report on Monday, March 10th. They set a “buy” rating on the stock. Piper Sandler restated an “overweight” rating and set a $9.00 price target (down previously from $10.00) on shares of Pulmonx in a report on Thursday, May 1st. Canaccord Genuity Group cut their price target on Pulmonx from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, May 1st. Finally, Morgan Stanley initiated coverage on Pulmonx in a report on Monday, March 10th. They set an “equal weight” rating on the stock. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Pulmonx has a consensus rating of “Moderate Buy” and a consensus price target of $11.59.

Pulmonx Trading Up 1.6%

LUNG opened at $3.18 on Wednesday. Pulmonx Co. has a one year low of $2.83 and a one year high of $9.37. The company has a market cap of $128.02 million, a P/E ratio of -2.21 and a beta of 0.65. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The business’s 50-day simple moving average is $4.49 and its 200-day simple moving average is $6.01.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The business had revenue of $22.54 million for the quarter, compared to the consensus estimate of $22.03 million. As a group, equities research analysts expect that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Insider Activity

In other news, Director Glendon E. French III sold 20,000 shares of the stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $7.85, for a total value of $157,000.00. Following the transaction, the director now owns 991,974 shares in the company, valued at approximately $7,786,995.90. This represents a 1.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 6.80% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.